MX371337B - Compuestos para protección de células. - Google Patents
Compuestos para protección de células.Info
- Publication number
- MX371337B MX371337B MX2015007883A MX2015007883A MX371337B MX 371337 B MX371337 B MX 371337B MX 2015007883 A MX2015007883 A MX 2015007883A MX 2015007883 A MX2015007883 A MX 2015007883A MX 371337 B MX371337 B MX 371337B
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- compounds
- protection
- group
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
- C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Abstract
La presente invención se refiere a un compuesto, (6-hidroxi-2, 5, 7,8- tetrametilcroman-2il) (4-(2-hidroxietil)piperazin-1- il) metanona en su forma racémica o enantiomérica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2010010A NL2010010C2 (en) | 2012-12-19 | 2012-12-19 | Compounds for protection of cells. |
| PCT/NL2013/050915 WO2014098586A1 (en) | 2012-12-19 | 2013-12-18 | Compounds for protection of cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015007883A MX2015007883A (es) | 2016-03-04 |
| MX371337B true MX371337B (es) | 2020-01-27 |
Family
ID=47790452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007883A MX371337B (es) | 2012-12-19 | 2013-12-18 | Compuestos para protección de células. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10123529B2 (es) |
| EP (2) | EP2935232B1 (es) |
| JP (2) | JP6359558B2 (es) |
| AU (1) | AU2013364538B9 (es) |
| CA (1) | CA2895701C (es) |
| CY (1) | CY1120682T1 (es) |
| DK (1) | DK2935232T3 (es) |
| ES (2) | ES2686599T3 (es) |
| HR (1) | HRP20181434T1 (es) |
| HU (1) | HUE039373T2 (es) |
| LT (1) | LT2935232T (es) |
| MX (1) | MX371337B (es) |
| NL (1) | NL2010010C2 (es) |
| PL (2) | PL2935232T3 (es) |
| PT (1) | PT2935232T (es) |
| RS (1) | RS57762B1 (es) |
| SI (1) | SI2935232T1 (es) |
| WO (1) | WO2014098586A1 (es) |
| ZA (1) | ZA201504602B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033757T2 (en) | 2012-07-12 | 2017-12-28 | Khondrion Ip B V | Chromanil derivatives for the treatment of mitochondrial disease |
| NL2010010C2 (en) * | 2012-12-19 | 2014-06-23 | Sulfateq B V | Compounds for protection of cells. |
| NL2013012B1 (en) | 2014-06-17 | 2016-07-05 | Sulfateq Bv | Compounds for the treatment of chronic obstructive airway diseases. |
| EP3297625B1 (en) * | 2015-05-22 | 2022-07-06 | Sulfateq B.V. | Compound for the prophylaxis or treatment of diabetic nephropathy or diabetic kidney disease |
| EP4241842A3 (en) | 2017-04-05 | 2023-11-08 | Khondrion Ip B.V. | Novel treatment of mitochondrial diseases |
| US20210128523A1 (en) | 2017-08-25 | 2021-05-06 | Sulfateq B.V. | Medicaments for the treatment of vasoconstriction related diseases or disorders |
| EP3672592A1 (en) * | 2017-08-25 | 2020-07-01 | Sulfateq B.V. | 6-chromanol derivatives for use as a medicament |
| AU2018371153B2 (en) | 2017-11-22 | 2023-07-13 | Khondrion Ip B.V. | Compounds as mPGES-1 inhibitors |
| WO2020077266A1 (en) * | 2018-10-11 | 2020-04-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for cell culture |
| NL2024431B1 (en) | 2019-12-11 | 2021-09-07 | Sulfateq Bv | Compounds for treatment of alzheimer’s disease |
| NL2025730B1 (en) | 2020-06-02 | 2022-01-20 | Sulfateq Bv | Compounds for treatment of sepsis |
| NL2026511B1 (en) | 2020-09-21 | 2022-05-24 | Sulfateq Bv | Compounds for treatment of heart failure |
| US20240051931A1 (en) * | 2020-12-03 | 2024-02-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Hdac inhibitors |
| NL2031091B1 (en) | 2022-02-28 | 2023-09-07 | Sulfateq Bv | Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA739471B (en) | 1972-12-22 | 1974-08-28 | Hoffmann La Roche | Chromane derivatives |
| EP0183869B1 (en) | 1984-12-06 | 1991-04-17 | Kuraray Co., Ltd. | Chroman compounds and their use |
| JPH0816108B2 (ja) | 1986-02-21 | 1996-02-21 | 株式会社クラレ | ３，４−ジヒドロ−２ｈ−ベンゾピラン誘導体及びその医薬用途 |
| CA1338012C (en) | 1987-04-27 | 1996-01-30 | John Michael Mccall | Pharmaceutically active amines |
| FR2676056B1 (fr) | 1991-05-03 | 1993-07-16 | Adir | Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| JP3074043B2 (ja) | 1991-09-06 | 2000-08-07 | エーザイ株式会社 | 動脈硬化治療・予防剤 |
| CA2073479A1 (en) * | 1992-07-08 | 1994-01-09 | Tai-Wing Wu | Synergistic compositions |
| ZA973848B (en) | 1996-05-06 | 1997-12-02 | Reddy Research Foundation | Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them. |
| JP3093170B2 (ja) | 1996-09-19 | 2000-10-03 | 株式会社ジャパンエナジー | ヒドロキノン誘導体及びその医薬用途 |
| US6809088B2 (en) * | 1997-03-24 | 2004-10-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| EP0894089B9 (en) * | 1997-05-02 | 2003-04-02 | Dr. Reddy's Laboratories Ltd. | Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| AU2474399A (en) | 1998-01-26 | 1999-08-09 | Mitokor | Mitochondria protecting agents for treating mitochondria associated diseases |
| US6002040A (en) | 1998-05-14 | 1999-12-14 | The Standard Oil Company | Reduced pressure drop in acrylonitrile absorber via direct contact spray heat exchange |
| AU4713499A (en) | 1998-06-27 | 2000-01-17 | Photogenesis, Inc. | Ophthalmic uses of ppargamma agonists and ppargamma antagonists |
| AR019190A1 (es) | 1998-07-08 | 2001-12-26 | Sod Conseils Rech Applic | Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos |
| WO2000006550A1 (fr) * | 1998-07-31 | 2000-02-10 | Nippon Soda Co., Ltd. | Composes phenylazole, procede de production desdits composes et medicaments pour le traitement de l'hyperlipidemie |
| EP1006108A1 (en) | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
| EP1221835B1 (en) | 1999-11-12 | 2003-04-09 | Elan Drug Delivery Limited | Platelet stabilisation |
| US6768008B2 (en) * | 2000-04-24 | 2004-07-27 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| AU2001259130A1 (en) * | 2000-04-24 | 2001-11-07 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| KR100389127B1 (ko) * | 2000-10-09 | 2003-06-25 | 동부한농화학 주식회사 | 벤조피라닐 헤테로고리 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물 |
| US7964339B2 (en) | 2007-02-09 | 2011-06-21 | Canadian Blood Services | Cold storage of modified platelets |
| CA2704473C (en) * | 2007-11-06 | 2016-10-04 | Edison Pharmaceuticals, Inc. | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| FR2945938B1 (fr) * | 2009-06-02 | 2011-06-10 | Oreal | Utilisation de derives d'acide chroman-2-carboxylique en coloration des fibres keratiniques humaines, composition les comprenant, procede de coloration et dispositif |
| NL2004569C2 (en) * | 2010-04-16 | 2011-10-18 | Angteq B V | Compounds for prevention of cell injury. |
| NL2010010C2 (en) * | 2012-12-19 | 2014-06-23 | Sulfateq B V | Compounds for protection of cells. |
| NL2013012B1 (en) * | 2014-06-17 | 2016-07-05 | Sulfateq Bv | Compounds for the treatment of chronic obstructive airway diseases. |
| EP3297625B1 (en) * | 2015-05-22 | 2022-07-06 | Sulfateq B.V. | Compound for the prophylaxis or treatment of diabetic nephropathy or diabetic kidney disease |
| NL2024431B1 (en) * | 2019-12-11 | 2021-09-07 | Sulfateq Bv | Compounds for treatment of alzheimer’s disease |
| NL2025730B1 (en) * | 2020-06-02 | 2022-01-20 | Sulfateq Bv | Compounds for treatment of sepsis |
| NL2026511B1 (en) * | 2020-09-21 | 2022-05-24 | Sulfateq Bv | Compounds for treatment of heart failure |
-
2012
- 2012-12-19 NL NL2010010A patent/NL2010010C2/en active
-
2013
- 2013-12-18 SI SI201331161T patent/SI2935232T1/sl unknown
- 2013-12-18 RS RS20181059A patent/RS57762B1/sr unknown
- 2013-12-18 EP EP13818495.7A patent/EP2935232B1/en active Active
- 2013-12-18 HU HUE13818495A patent/HUE039373T2/hu unknown
- 2013-12-18 DK DK13818495.7T patent/DK2935232T3/en active
- 2013-12-18 PL PL13818495T patent/PL2935232T3/pl unknown
- 2013-12-18 US US14/654,046 patent/US10123529B2/en active Active
- 2013-12-18 PT PT13818495T patent/PT2935232T/pt unknown
- 2013-12-18 AU AU2013364538A patent/AU2013364538B9/en active Active
- 2013-12-18 PL PL18174182.8T patent/PL3388426T3/pl unknown
- 2013-12-18 LT LTEP13818495.7T patent/LT2935232T/lt unknown
- 2013-12-18 ES ES13818495.7T patent/ES2686599T3/es active Active
- 2013-12-18 WO PCT/NL2013/050915 patent/WO2014098586A1/en active Application Filing
- 2013-12-18 MX MX2015007883A patent/MX371337B/es active IP Right Grant
- 2013-12-18 ES ES18174182T patent/ES2954292T3/es active Active
- 2013-12-18 JP JP2015549299A patent/JP6359558B2/ja active Active
- 2013-12-18 CA CA2895701A patent/CA2895701C/en active Active
- 2013-12-18 EP EP18174182.8A patent/EP3388426B1/en active Active
-
2015
- 2015-06-25 ZA ZA2015/04602A patent/ZA201504602B/en unknown
-
2018
- 2018-06-20 JP JP2018116950A patent/JP6684861B2/ja active Active
- 2018-09-07 HR HRP20181434TT patent/HRP20181434T1/hr unknown
- 2018-09-07 CY CY181100936T patent/CY1120682T1/el unknown
- 2018-09-27 US US16/143,471 patent/US11006626B2/en active Active
-
2021
- 2021-04-15 US US17/231,048 patent/US20210227822A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015007883A (es) | Compuestos para protección de células. | |
| IN2014CN04530A (es) | ||
| MX2013006926A (es) | Compuestos y composiciones fotocromicas. | |
| IN2014MN02496A (es) | ||
| UA111626C2 (uk) | Похідні дигідрохінолін-2-ону | |
| IN2014MN02459A (es) | ||
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| SG195319A1 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| EP4230631A3 (en) | Process for making trisubstituted silyloxyethyl triflates | |
| MX2013012749A (es) | Inhibidores del virus de la hepatitis c. | |
| MY169267A (en) | New aryl-quinoline derivatives | |
| IN2013MN02014A (es) | ||
| IN2014MN01521A (es) | ||
| MX2016005993A (es) | Anfifilos biscationicos y triscationicos como agentes antimicrobianos. | |
| IN2014CN04449A (es) | ||
| PH12015501429A1 (en) | Herbicidal composition | |
| IN2012DN00773A (es) | ||
| PH12015501400A1 (en) | Herbicidal composition comprising a cornexistin | |
| EA201390374A1 (ru) | Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина | |
| MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
| AR077332A1 (es) | Procesos para la alquilacion de pirazoles | |
| IN2015DN02514A (es) | ||
| IN2014CN04279A (es) | ||
| IN2013MU03015A (es) | ||
| MX2013013021A (es) | Nuevos compuestos de hexahidropirroloimidazolona. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |